Back A A A Font Size Receive E-mail Alerts Press Releases

Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC


Shanghai, China – On April 1, MicroPort Scientific Corporation ("MPSC") is pleased to announce that effective immediately Mr. Jonathan Chen has been promoted to Chief International Business Officer of MPSC.
Mr. Jonathan Chen joint in MPSC in July of 2012, and originally served as the Executive Vice President of International Operations and Investor Relations of MPSC. He has become the Chairperson of MPSC's Intercontinental Executive Committee ("IEC") since September, 2015. Mr. Chen's primary responsibilities include growing the company's International business in markets outside of China, primarily in the markets of the U.S, Europe and South America.
Mr. Chen has over 21 years of experience in the medical device industry. Prior to joining the company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for six years, where he was Senior Vice President of Business Development. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons. He advised on over $3 billion in Mergers & Acquisitions transactions.
Mr. Chen has a Bachelor of Arts degree in Economics and a Bachelor of Sciences degree with honors in Biological Sciences from Stanford University.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:MicroPort®'s Firehawk® Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial
[Next]:MicroPort® CardioFlow Releases One-year Clinical Outcome of VitaFlow®